/ News, Research

11.8 million CHF for clinical trials of novel arthritis repair (Martin Lab)

Surgeon operating

Human articular cartilage defects can be treated with cells taken from the nasal septum. (Image: University of Basel, Christian Flierl)

Swiss government and European Union award 11.8 million CHF for next generation clinical trials of novel arthritis repair. The researchers at the Department of Biomedicine, University of Basel and University Hospital Basel, are actively recruiting for clinical trials.

The Department of Biomedicine at the University of Basel and the University Hospital Basel, have announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans. The procedure called Nasal Chondrocyte Tissue-Engineered Cartilage, or N-TEC, provides an innovative alternative to cure confined knee cartilage lesions as well as to address degenerative OA cases that have to date required knee joint replacements – prosthetics that routinely need replacing after 15-20 years.

The team at Basel is spearheading the next-generation human clinical trials that will take place at multiple sites across Europe, including Switzerland, Germany, Italy, Croatia, Sweden, Austria and Poland. The Swiss government and EU have awarded the N-TEC program $13.1 million (11.8 million CHF) in funding for these OA clinical trials – and the team is continuing to seek additional funding to expand these trials and deliver this promising regenerative OA treatment to joints other than knees. These clinical trials are open to qualified patients from around the world, including the United States.

Click here to read more.